Genetics of therapy-related myelodysplasia and acute myeloid leukemia

Leukemia
J Pedersen-BjergaardD H Christiansen

Abstract

Myelodysplasia (MDS) and acute myeloid leukemia (AML) are heterogeneous, closely associated diseases arising de novo or following chemotherapy with alkylating agents, topoisomerase II inhibitors, or after radiotherapy. Whereas de novo MDS and AML are almost always subclassified according to cytogenetic characteristics, therapy-related MDS (t-MDS) and therapy-related AML (t-AML) are often considered as separate entities and are not subdivided. Alternative genetic pathways were previously proposed in t-MDS and t-AML based on cytogenetic characteristics. An increasing number of gene mutations are now observed to cluster differently in these pathways with an identical pattern in de novo and in t-MDS and t-AML. An association is observed between activating mutations of genes in the tyrosine kinase RAS-BRAF signal-transduction pathway (Class I mutations) and inactivating mutations of genes encoding hematopoietic transcription factors (Class II mutations). Point mutations of AML1 and RAS seem to cooperate and predispose to progression from t-MDS to t-AML. Recently, critical genetic effects underlying 5q-/-5 and 7q-/-7 have been proposed. Their association and cooperation with point mutations of p53 and AML1, respectively, extend the s...Continue Reading

References

May 20, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J Pedersen-BjergaardB Johansson
Mar 6, 2002·Blood·Jens Pedersen-BjergaardClaus Nerlov
Aug 27, 2002·Annual Review of Genomics and Human Genetics·Louise M Kelly, D Gary Gilliland
Jan 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stefan FröhlingKonstanze Döhner
Jan 22, 2005·The New England Journal of Medicine·Brunangelo FaliniUNKNOWN GIMEMA Acute Leukemia Working Party
Jan 26, 2006·Blood·Ulrike BacherSusanne Schnittger
Aug 9, 2006·DNA Repair·Yanming Zhang, Janet D Rowley
Sep 19, 2006·Proceedings of the National Academy of Sciences of the United States of America·Elaine M SloandNeal S Young
Dec 8, 2006·The New England Journal of Medicine·Peter J Campbell, Anthony R Green

❮ Previous
Next ❯

Citations

Mar 3, 2010·Annals of Hematology·Ulrike BacherTorsten Haferlach
May 27, 2011·Cancer Chemotherapy and Pharmacology·J Lee VillanoLinda R Bressler
Feb 26, 2013·Current Treatment Options in Oncology·Karen Seiter
Jan 19, 2010·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Melanie Joannides, David Grimwade
May 1, 2012·Chemical Research in Toxicology·Liping WangQiang Ma
Apr 16, 2011·Leukemia·L S SteelmanJ A McCubrey
Jun 27, 2009·Nature Genetics·Charles G Mullighan
Jul 1, 2011·The New England Journal of Medicine·Rafael BejarBenjamin L Ebert
Jul 1, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·V PullarkatS J Forman
Jan 15, 2010·Annual Review of Public Health·Martyn T Smith
Jan 9, 2010·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Luoping ZhangQing Lan
May 28, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Brian ParkinSami N Malek
Jul 1, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ann Mullally, Benjamin L Ebert
Jun 22, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sigurdur Y KristinssonLynn R Goldin
Jan 9, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael Zach KoontzRanjana H Advani
Aug 2, 2012·International Journal of Environmental Research and Public Health·Reuben ThomasLuoping Zhang
Oct 16, 2012·International Journal of Environmental Research and Public Health·Ida CasorelliMargherita Bignami
Aug 21, 2013·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Ya-zhou HeYan-hong Zhou
Apr 16, 2014·Mutation Research. Reviews in Mutation Research·David A EastmondBabasaheb Sonawane
Apr 19, 2011·Expert Review of Hematology·Wan-Jen Hong, Bruno C Medeiros
Feb 14, 2015·Expert Opinion on Drug Safety·Myrna Candelaria, Alfonso Dueñas-Gonzalez
Jan 21, 2014·Human Pathology·Pasquale TripputiAlberto Zanella
Aug 29, 2013·Protein & Cell·Grace L PeloquinAmir T Fathi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.